Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2011 1
2012 1
2013 1
2014 1
2015 2
2016 3
2017 1
2018 3
2020 3
2021 3
2022 2
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Correction: Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Bozorgmehr F, Chung I, Christopoulos P, Krisam J, Schneider MA, Brückner L, Mueller DW, Thomas M, Rieken S. Bozorgmehr F, et al. Among authors: chung i. BMC Cancer. 2023 Aug 10;23(1):740. doi: 10.1186/s12885-023-11270-x. BMC Cancer. 2023. PMID: 37563548 Free PMC article. No abstract available.
Protocol of the TREASURE study: Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease - a randomized, open-label, multicenter phase II trial.
Bozorgmehr F, Christopoulos P, Chung I, Cvetkovic J, Feißt M, Krisam J, Schneider MA, Heußel CP, Kreuter M, Müller DW, Thomas M, Rieken S. Bozorgmehr F, et al. Among authors: chung i. BMC Cancer. 2022 Sep 24;22(1):1011. doi: 10.1186/s12885-022-10074-9. BMC Cancer. 2022. PMID: 36153496 Free PMC article.
PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic Power.
Poos AM, Schroeder C, Jaishankar N, Röll D, Oswald M, Meiners J, Braun DM, Knotz C, Frank L, Gunkel M, Spilger R, Wollmann T, Polonski A, Makrypidi-Fraune G, Fraune C, Graefen M, Chung I, Stenzel A, Erfle H, Rohr K, Baniahmad A, Sauter G, Rippe K, Simon R, Koenig R. Poos AM, et al. Among authors: chung i. Cancers (Basel). 2022 Mar 1;14(5):1267. doi: 10.3390/cancers14051267. Cancers (Basel). 2022. PMID: 35267575 Free PMC article.
Brigatinib versus other second-generation ALK inhibitors as initial treatment of anaplastic lymphoma kinase positive non-small cell lung cancer with deep phenotyping: study protocol of the ABP trial.
Christopoulos P, Bozorgmehr F, Brückner L, Chung I, Krisam J, Schneider MA, Stenzinger A, Eickhoff R, Mueller DW, Thomas M. Christopoulos P, et al. Among authors: chung i. BMC Cancer. 2021 Jun 28;21(1):743. doi: 10.1186/s12885-021-08460-w. BMC Cancer. 2021. PMID: 34182952 Free PMC article. Clinical Trial.
De Novo Versus Secondary Metastatic EGFR-Mutated Non-Small-Cell Lung Cancer.
Bozorgmehr F, Kazdal D, Chung I, Kirchner M, Magios N, Kriegsmann M, Allgäuer M, Klotz LV, Muley T, El Shafie RA, Fischer JR, Faehling M, Stenzinger A, Thomas M, Christopoulos P. Bozorgmehr F, et al. Among authors: chung i. Front Oncol. 2021 Apr 9;11:640048. doi: 10.3389/fonc.2021.640048. eCollection 2021. Front Oncol. 2021. PMID: 33898315 Free PMC article.
Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Bozorgmehr F, Chung I, Christopoulos P, Krisam J, Schneider MA, Brückner L, Mueller DW, Thomas M, Rieken S. Bozorgmehr F, et al. Among authors: chung i. BMC Cancer. 2020 Aug 26;20(1):806. doi: 10.1186/s12885-020-07264-8. BMC Cancer. 2020. PMID: 32842974 Free PMC article.
24 results